FDA approves Daytrana ADHD patch

The FDA has approved Daytrana, the first patch for treating ADHD. The therapy was developed by Noven Pharmaceuticals and Shire, which has the global marketing license. The companies said the new treatment would be released in mid-2006. It's designed to be worn by children throughout the day, who will receive a steady dose of the therapy. That is intended to help young patients who would have trouble staying up with oral formulas. Noven received an up-front payment of $25 million and stands to gain up to $125 million in milestones.

- here's a MarketWatch report on the patch